kidney disease glp 1 Glucagon-like Peptide Receptor Agonists and Outcomes in the Era of Personalized Medicine: Focus on Albuminuria GLP-1 RAs, Other Agents, Underused

Ensuring equitable access and strengthening health systems will be essential to prevent widening health disparities.AgendaCo-chairsDr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMAModeratorDr Gaya Manori Gamhewage, Director, Department of Communication, WHOWelcomingDr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMAPresentation:WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adultsDr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr

From potential benefits to considerations and risks, heres what to know about how GLP1 treatments support overall wellness.

GLP-1 medications are prescribed for reasons beyond weight management, including type 2 diabetes, cardiovascular risk reduction, and metabolic health optimization

New trial data for Amgen's GLP-1 drug MariTide shows a weight loss of 20 percent in non-diabetic participants with obesity or overweight.

however, the benefits of these medications come at a significant financial cost to patie

Explore the potential link between tirzepatide and hiccups, understand the mechanisms involved, and discover practical strategies for managing this side effect whilst treating type 2 diabetes effectively.